Neurocrine Biosciences, Inc.
NASDAQ: NBIX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kyle W. Gano
- Employees
- 1,800
- Headquarters
- San Diego, United States
- IPO year
- 1996
- Market cap
- $15.9B
- Website
- https://www.neurocrine.com
Loading NBIX…
Loading profile data…Frequently asked questions about NBIX
What does Neurocrine Biosciences, Inc. (NBIX) do?
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and...
Where does NBIX trade?
Neurocrine Biosciences, Inc. (NBIX) trades on the NASDAQ Global Select.
What sector is NBIX in?
Neurocrine Biosciences, Inc. (NBIX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Neurocrine Biosciences, Inc.?
Kyle W. Gano is the chief executive officer of Neurocrine Biosciences, Inc. (NBIX).
Where is Neurocrine Biosciences, Inc. headquartered?
Neurocrine Biosciences, Inc. is headquartered in United States.
Does NBIX pay a dividend?
Neurocrine Biosciences, Inc. (NBIX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NBIX go public?
Neurocrine Biosciences, Inc. (NBIX) completed its initial public offering in 1996.